G280 Stock Chart & Stats
€7.70
€0.00(0.00%)
At close: 4:00 PM EDT
€7.70
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.90 - €37.10
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€40.91M
Enterprise Value€38.83
Total Cash (Recent Filing)€1.08M
Total Debt (Recent Filing)€3.04M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.83
Shares Outstanding6,511,540
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced DebtDebt reduction improves the company’s leverage profile and lowers the burden of financing obligations compared with earlier periods. While negative equity remains a constraint, a smaller debt base can preserve more flexibility as management funds clinical translation and seeks a path toward commercialization.
Loss ImprovementThe reported improvement in loss magnitude indicates some progress in controlling expenses or reducing operating losses, even though the company remains unprofitable. If sustained, better cost discipline could extend available funding and support investment in its T-cell therapy programs.
Nasdaq Compliance RestoredRestored Nasdaq compliance removes an immediate delisting issue and supports continued access to public-market infrastructure. Maintaining a listed venue can help preserve trading liquidity, stakeholder credibility, and potential access to financing while the company remains in development.
Bears Say
No Commercial RevenueZero revenue means the business has not yet demonstrated commercial product demand or an operating revenue base. Continued dependence on research and clinical translation leaves future value tied to successful development and commercialization rather than established sales.
Persistent Cash BurnSustained negative operating and free cash flow shows that operations consume cash rather than generate it. Without a revenue ramp, the company must continue funding development externally, creating ongoing financing pressure and potential dilution risk over the coming quarters.
Negative Equity And Limited CushionNegative shareholder equity weakens the balance sheet and limits financial flexibility, while relatively small total assets provide little cushion if losses continue. This combination can make it harder to absorb setbacks or fund development without additional capital.
Tevogen Bio Holdings News
G280 FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was €6.90 and its highest was €37.10 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is €40.91M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 72 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Aug 13, 2026. The company reported -€1.314 earnings per share for the quarter.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 6,511,540 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -€1.314 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in DE:G280
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―